Malignant pleural mesothelioma (MPM) is an aggressive tumor linked to asbestos exposure. Although the risk factors for MPM are well-known, the majority of MPM patients are diagnosed at an advanced stage and have a very poor prognosis. Circulating biomarkers for early diagnosis remain to be identified, and the current standard for MPM diagnosis relies on pleural biopsies. Robust non-invasive tests for the screening of asbestos-exposed subjects are therefore an important unmet clinical need. This review provides a critical summary of recent liquid biopsy-based studies aimed at discovering novel blood-based circulating biomarkers for the early diagnosis and prognostic stratification of MPM patients.
CITATION STYLE
Cavallari, I., Urso, L., Sharova, E., Pasello, G., & Ciminale, V. (2019). Liquid biopsy in malignant pleural mesothelioma: State of the art, pitfalls, and perspectives. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2019.00740
Mendeley helps you to discover research relevant for your work.